HµRELdogTMDeveloped through a funded R&D collaboration with UCB Pharma, HµRELdogTM, the first characterized canine primary hepatocyte-based 3D tissue culture, complements the Company’s HµRELhumanTM, HµRELratTM, and HµRELprimateTM products and enables inter-species comparative studies. Published in Toxicology and Applied Pharmacology.
Based on the results of a 51-compound study they performed, UCB scientists concluded that the HµRELdogTM co-culture constitutes “a promising model for chronic studies in metabolism and toxicity” that “outperforms two other widely used cellular systems and represents a novel and effective platform for predicting pharmacokinetics and toxicity profiles of drugs under development.”
HµRELviralTMLong-enduring infectious liver disease platform
HµRELfluxTMa new, patent-pending